Sign in
4

Changes in Ownership

Fulcrum Therapeutics, Inc. Filed Acc 0000899243-22-021250

Director sold 66,622 shares at an average $8.00 ($532,810)

  • Director acquired 66,622 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Gould Robert J · Director

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2022-06-02 Exercise or conversion : show line 1 in the form +16,689 $7.84 $130,842 523,319 D
2022-06-02 Sale : show line 2 in the form −16,689 $7.92 $132,162 506,630 D
2022-06-03 Exercise or conversion : show line 3 in the form +25,551 $7.84 $200,320 532,181 D
2022-06-03 Sale : show line 4 in the form −25,551 $7.95 $203,056 506,630 D
2022-06-06 Exercise or conversion : show line 5 in the form +24,382 $7.84 $191,155 531,012 D
2022-06-06 Sale : show line 6 in the form −24,382 $8.10 $197,592 506,630 D
Open-market sales · 66,622 sh · avg $8.00 · $532,810

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2022-06-02 Exercise or conversion : show line 7 in the form Stock Option (right to buy) −16,689 207,891 D
2022-06-03 Exercise or conversion : show line 8 in the form Stock Option (right to buy) −25,551 182,340 D
2022-06-06 Exercise or conversion : show line 9 in the form Stock Option (right to buy) −24,382 157,958 D
Loading xslF345X03/doc4.xml…